Novo Nordisk’s Wegovy Gets A Logistics Boost – EU Eases Shipping Rules

• The company stated that the update applies only to the Wegovy injection, not the pill.
• The change is expected to reduce reliance on cold chain logistics, which is more expensive, it added.
• Earlier this week, Novo announced the U.S. availability of its higher-dose Wegovy injection.

Novo Nordisk (NVO) on Thursday announced that the European Medicines Agency approved flexible delivery conditions for its blockbuster Wegovy injection, allowing transport at up to 30°C for up to 48 hours, potentially easing supply chain constraints for GLP-1 treatments.

NVO shares were down 1.4% at the time of writing.

Lower Transportation Costs

The change is expected to simplify distribution by reducing reliance on cold chain logistics, potentially lowering delivery costs and improving supply chain efficiency for pharmacies and online providers.

Novo added that there are no changes to patient use guidelines, and the update applies only to the Wegovy injection, not the pill, which is currently pending an EU regulatory decision.

The firm’s management also noted the growing trend of home delivery of medicines, given the convenience. 

“People with obesity using prescription medicine may also face stigma, and we are therefore excited about the opportunity to reduce distribution complexity while further enabling discrete home delivery options,” said Mike Doustdar, CEO and President of Novo Nordisk.

US Availability Of Novo’s Higher Dose Wegovy Injection 

Earlier this week, Novo Nordisk announced the U.S. availability of its higher-dose Wegovy injection (7.2 mg), accessible through more than 70,000 pharmacies and select telehealth providers. The new dose offers the highest weight loss seen with Wegovy to date.

The approval was based on late-stage trial results showing 89% of patients achieved at least 5% weight loss over 72 weeks, compared to 38% on placebo. 

Previously, the highest approved dose was 2.4 mg. Novo Nordisk said self-paying patients can expect a monthly price of around $399.

How Did Retail Traders React?

Retail sentiment for NVO on Stocktwits has remained ‘bearish’ for a while. It was ‘neutral’ a month earlier.

One user sees an opportunity to buy the dip.

NVO shares have shed nearly 28% so far in 2026.

For updates and corrections, email newsroom[at]stocktwits[dot]com.